Medico-social aspects of hepatocellular carcinoma

Niyaz Malayev 1 * , Samat Saparbayev 2, Saule Kubekova 3, Nurgul Kereyeva 2
More Detail
1 Department of General and Thoracic Surgery, National Scientific Medical Center, Astana, Kazakhstan
2 Oncology Department, West Kazakhstan Medical University, Aktobe, Kazakhstan
3 Department of Cardiology, Astana Medical University, Astana, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 20, Issue 3, pp. 4-7. https://doi.org/10.23950/jcmk/13257
OPEN ACCESS 809 Views 695 Downloads
Download Full Text (PDF)

ABSTRACT

Oncological diseases are one of the leading health problems both in the world and in Kazakhstan, second only to cardiovascular diseases. Hepatocellular carcinoma occupies the 8th place in the structure of oncopathologies, has an unfavorable prognosis and an unfavorable course. According to the WHO, more than 1.3 million people die each year from hepatocellular carcinoma (HCC). The incidence rate of HCC in Kazakhstan is up to 5.5 cases per 100 thousand of the population, and the mortality rate remains high (about 1000 people annually). In 2017, 82.3% of HCC patients died before the end of the year. Five-year survival in HCC does not exceed 18%, and postoperative recurrence is about 50%.
Keywords: social, hepatocellular carcinoma, incidence, healthcare

CITATION

Malayev N, Saparbayev S, Kubekova S, Kereyeva N. Medico-social aspects of hepatocellular carcinoma. J CLIN MED KAZ. 2023;20(3):4-7. https://doi.org/10.23950/jcmk/13257

REFERENCES

  • https://www.who.int/ru/news-room/fact-sheets/detail/cancer
  • Zdorov'e naselenija Respubliki Kazahstan i dejatel'nost' organizacii zdravoohranenija v 2020 g.g. Statisticheskij sbornik.- Nur-Sultan.-2020
  • https://www.who.int/publications/m/item/cancer-kaz-2020
  • Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380:1450–62. https://doi.org/10.1056/NEJMra1713263
  • Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–604. https://doi.org/10.1038/s41575-019-0186-y
  • Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst. 2017. 109. https://doi.org/10.1093/jnci/djx030
  • Li X, Lin J, Pan Y, Cui P, Xia J. Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma. Technol Cancer Res Treat. 2021;20. https://doi.org/10.1177/15330338211041425
  • Isamatov B.K., Kuralbek A.O., Satybaldy M.B., Kenzhe A.E. Analiz pokazatelej zabolevaemosti gepatocelljuljarnoj karcinomy v Respublike Kazahstan. Vestnik KazNMU. 2019; 9:361.
  • Kaprin A.D., Starinskij V.V., Grecova O.P. i dr. Populjacionnyj registr onkologicheskih bol'nyh v Rossijskoj Federacii. populjacionnyj registr onkologicheskih bol'nyh v Rossijskoj Federacii. PUBLIC HEALTH PANORAMA. 2019; 5(1):1–121. https://doi.org/10.18027/2224-5057-2019-9-1-6-9
  • Smailova D.S. Puti uluchshenija kachestva jekonomicheskoj jeffektivnosti Nacional'noj skriningovoj programmy na rannee vyjavlenie onkologicheskih zabolevanij: dis. … dok. fil. nauk: 6D110200. Ibraev S.E. NAO med.un-t. Semej, 2020; 7.
  • Omarova I.M., Kozhamberdin K.E., Abdrahmanova A.Zh. Targetnaja terapija pervichnogo raka pecheni. Medicina i jekologija. 2011; 4:14.
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590
  • Konopljanik O.V., Gusakova N.V., Gomoljako A.V., Kul'chik Je.O. Analiz zabolevaemosti i vyzhivaemosti pri pervichnom rake pecheni. Vestnik Smolenskoj gosudarstvennoj medicinskoj akademii. 2020; 2:225. https://doi.org/10.37903/vsgma.2020:2.30
  • Ferlay J, Ervik M, Dikshit R, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 1. International Agency for Research for Cancer; Lyon: France. 2013. https://doi.org/10.1002/ijc.29210
  • Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844-55. https://doi.org/10.1136/gutjnl-2013-306627
  • Abdrahmanov D.T., Breder V.V., Bolotina L.V., Kosyrev V.Ju. Neoperabel'nyj gepatocelljuljarnyj rak: novye vozmozhnosti i perspektivy terapii. Sovremennaja onkologija. 2019; 2:10. https://doi.org/10.26442/18151434.2019.2.190410
  • Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC). Korea. 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver. 2019; 13(3): 227–299. https://doi.org/10.5009/gnl19024
  • https://apps.who.int/iris/bitstream/handle/10665/44203/9789244563878
  • Kamhen V.B. Jepidemilogicheskie aspekty zabolevaemosti zlokachestvennymi novoobrazovanijami v Kazahstane. Unikal'nye issledovanija XXI veka. 2015; 61-62.
  • Musina D.S. Puti uluchshenija kachestva i povyshenija jeffektivnosti nacional'noj skriningovoj programmy na ranee vyjavlenie onkologicheskih zabolevanij. Nauka i zdravoohranenie. 2017; 1:99.
  • Jashhjuk I.V. Skriningi zlokachestvennyh obrazovanij. Menedzher zdravoohranenija. 2014; 4:66-67.
  • Arybzhanov D.T., Navesova V.Sh., Maklakova E.Je., Tasbulatova G.E. Opyt regional'noj himioterapii pervichnogo raka pecheni. Cibirskij onkologicheskij zhurnal. 2011; 2:11.
  • Breder V.V. Gepatocelljuljarnyj rak v Rossijskoj Federacii. Medicinskij sovet. 2016; 10:10-11. https://doi.org/10.21518/2079-701X-2017-14-11-23
  • Pinker K, Shitano F, Sala E, Do RK, Young RJ, Wibmer AG, et al. Background, current role, and potential applications of radiogenomics. J Magn Reson Imaging. 2018;47(3):604–20. https://doi.org/10.1002/jmri.25870
  • Mazurowski MA. Radiogenomics: what it is and why it is important. J Am Coll Radiol. 2015;12(8):862–6. https://doi.org/10.1016/j.jacr.2015.04.019
  • Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: A prospective analysis study. Lancet Oncol. 2012;13(1):65–77. https://doi.org/10.1016/S1470-2045(11)70302-3
  • Cherukuri AR, Lubner MG, Zea R, Hinshaw JL, Lubner SJ,Matkowskyj KA, et al. Tissue sampling in the era of precision medicine: comparison of percutaneous biopsies performed for clinical trials or tumor genomics versus routine clinical care. Abdom Radiol (NY). 2019;44(6):2074–80. https://doi.org/10.1007/s00261-018-1702-1
  • Ahmed M, Solbiati L, Brace CL, et al; International Working Group on Image-Guided Tumor Ablation; Interventional Oncology Sans Frontières Expert Panel; Technology Assessment Committee of the Society of Interventional Radiology; Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe. Image-guided tumor ablation: standardization of terminology and reporting criteria–a 10-year update. J Vasc Interv Radiol. 2014;25(11):1691–705.e4. https://doi.org/10.1016/j.jvir.2014.09.005
  • Halperin EC, Perez CA, Brady LW. Perez and Brady’s Principles and Practice of Radiation Oncology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008
  • Llovet JM, Real MI, Montaña X, et al; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–1739. https://doi.org/10.1016/S0140-6736(02)08649-X
  • Riaz A, Memon K, Miller FH, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54(4):695–704. https://doi.org/10.1016/j.jhep.2010.10.004
  • Hickey R, Vouche M, Sze DY, et al. Cancer concepts and principles: primer for the interventional oncologist-part I. J Vasc Interv Radiol. 2013;24(8):1157–1164. https://doi.org/10.1016/j.jvir.2013.04.024
  • Bergmann L, Berns B, Dalgleish AG, et al; Biotherapy Development Association. Investigator-initiated trials of targeted oncology agents: why independent research is at risk? Ann Oncol. 2010; 21(8):1573–1578. https://doi.org/10.1093/annonc/mdq018
  • Pokazateli onkologicheskoj sluzhby Respubliki Kazahstan za 2019 god: statisticheskie materialy. KazNIIOIR – Almaty, 2020. – C. 143
  • Pokazateli onkologicheskoj sluzhby Respubliki Kazahstan za 2018 god: statisticheskie materialy. KazNIIOIR – Almaty, 2019 – S. 152
  • Pokazateli onkologicheskoj sluzhby Respubliki Kazahstan za 2020 god (statisticheskie materialy. KazNIIOIR – Almaty, 2021 – S. 135
  • Postanovlenie Pravitel'stva Respubliki Kazahstan ot 29 ijunja 2018 goda № 395. Ob utverzhdenii Kompleksnogo plana po bor'be s onkologicheskimi zabolevanijami v Respublike Kazahstan na 2018 – 2022 gody.